within Pharmacolibrary.Drugs.ATC.C;

model C01BD04
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.9,
    Cl             = 5.183333333333333e-05,
    adminDuration  = 600,
    adminMass      = 500 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00361,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.02666666666666667,
    Tlag           = 10.200000000000001,            
    Vdp             = 0.00257,
    k12             = 1.31,
    k21             = 1.31
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C01BD04</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Dofetilide is a class III antiarrhythmic agent used for the maintenance of normal sinus rhythm in patients with atrial fibrillation or atrial flutter. It is approved for clinical use and acts primarily by blocking the cardiac potassium channel to prolong repolarization.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics reported for healthy adult volunteers after oral administration.</p><h4>References</h4><ol><li><p>Allen, MJ, et al., &amp; Oliver, SD (2000). The pharmacokinetics and pharmacodynamics of oral dofetilide after twice daily and three times daily dosing. <i>British journal of clinical pharmacology</i> 50(3) 247–253. DOI:<a href=\"https://doi.org/10.1046/j.1365-2125.2000.00243.x\">10.1046/j.1365-2125.2000.00243.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/10971309/\">https://pubmed.ncbi.nlm.nih.gov/10971309</a></p></li><li><p>Mounsey, JP, &amp; DiMarco, JP (2000). Cardiovascular drugs. Dofetilide. <i>Circulation</i> 102(21) 2665–2670. DOI:<a href=\"https://doi.org/10.1161/01.cir.102.21.2665\">10.1161/01.cir.102.21.2665</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/11085972/\">https://pubmed.ncbi.nlm.nih.gov/11085972</a></p></li><li><p>Smith, DA, et al., &amp; Walker, DK (1992). Pharmacokinetics and metabolism of dofetilide in mouse, rat, dog and man. <i>Xenobiotica; the fate of foreign compounds in biological systems</i> 22(6) 709–719. DOI:<a href=\"https://doi.org/10.3109/00498259209053133\">10.3109/00498259209053133</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/1441594/\">https://pubmed.ncbi.nlm.nih.gov/1441594</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C01BD04;
